Oncology · NSCLCTrial Updateclinicalmid-term

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:30:46 PM

Assessment confidence: 54% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The KEYMAKER-U01 study represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC) by exploring pembrolizumab both alone and in combination with chemotherapy. Its outcomes could redefine competitive dynamics in the NSCLC landscape, particularly against other PD-1/PD-L1 inhibitors. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this study to assess the potential for expanded indications for pembrolizumab. The strongest clinical anchor is KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (merck sharp dohme llc). In lung cancer, 5 regulatory and 6 competitive items passed relevance filtering for Merck Sharp & Dohme LLC.

Competitive Pressure

The most relevant competitive pressure comes from Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna (Humanexa Signals) — sub-indication match (lung cancer); entity match (pembrolizumab). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This umbrella master protocol may enhance Merck's competitive position in the NSCLC treatment landscape, especially against other PD-1/PD-L1 inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (Merck); Regulatory pathway relevance (indication). The study's findings may influence future regulatory approvals and labeling for pembrolizumab, depending on the efficacy and safety results across diverse NSCLC populations.

Key Risks

Elevated medium regulatory exposure for Merck Sharp & Dohme LLC could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Merck Sharp & Dohme LLC through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Successful results from this study could lead to expanded indications for pembrolizumab, enhancing Merck's market share and revenue potential in the oncology sector.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · Immunotherapy · Trial Update · If durvalumab demonstrates a significant survival benefit, it could position AstraZeneca favorably against competitors in the NSCLC immunotherapy space.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Follow the enrollment progress and results from the substudies to gauge efficacy and safety in diverse NSCLC populations.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (indication)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (indication)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (merck sharp dohme llc)
FDA document
View source
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (merck sharp dohme llc)
FDA document
View source
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
ClinicalTrials.govmedium relevance
Entity match (merck sharp dohme llc)
FDA document
View source
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
ClinicalTrials.govmedium relevance
Entity match (merck sharp dohme llc)
FDA document
View source
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
ClinicalTrials.govmedium relevance
Entity match (merck sharp dohme llc)
FDA document
View source
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
ClinicalTrials.govmedium relevance
Entity match (merck sharp dohme llc)
FDA document
View source

Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (AstraZeneca)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment
Humanexa Signalsmedium relevance
Entity match (pembrolizumab)

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (PD-L1)
FDA document
View source
CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Commercial impact

high

Successful results from this study could lead to expanded indications for pembrolizumab, enhancing Merck's market share and revenue potential in the oncology sector.

Regulatory impact

medium

The study's findings may influence future regulatory approvals and labeling for pembrolizumab, depending on the efficacy and safety results across diverse NSCLC populations.

What to watch

Follow the enrollment progress and results from the substudies to gauge efficacy and safety in diverse NSCLC populations.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.